JP2023533203A5 - - Google Patents
Info
- Publication number
- JP2023533203A5 JP2023533203A5 JP2022580090A JP2022580090A JP2023533203A5 JP 2023533203 A5 JP2023533203 A5 JP 2023533203A5 JP 2022580090 A JP2022580090 A JP 2022580090A JP 2022580090 A JP2022580090 A JP 2022580090A JP 2023533203 A5 JP2023533203 A5 JP 2023533203A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- unsubstituted
- compound according
- substituted
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203650A JP2026035702A (ja) | 2020-06-24 | 2025-11-26 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043555P | 2020-06-24 | 2020-06-24 | |
| US63/043,555 | 2020-06-24 | ||
| PCT/US2021/038618 WO2021262810A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203650A Division JP2026035702A (ja) | 2020-06-24 | 2025-11-26 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533203A JP2023533203A (ja) | 2023-08-02 |
| JP2023533203A5 true JP2023533203A5 (https=) | 2024-06-07 |
| JP7781792B2 JP7781792B2 (ja) | 2025-12-08 |
Family
ID=79032408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580090A Active JP7781792B2 (ja) | 2020-06-24 | 2021-06-23 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| JP2025203650A Pending JP2026035702A (ja) | 2020-06-24 | 2025-11-26 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203650A Pending JP2026035702A (ja) | 2020-06-24 | 2025-11-26 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11634407B2 (https=) |
| EP (1) | EP4171566A4 (https=) |
| JP (2) | JP7781792B2 (https=) |
| KR (1) | KR20230027066A (https=) |
| CN (2) | CN120441548A (https=) |
| AR (1) | AR122723A1 (https=) |
| AU (1) | AU2021296833A1 (https=) |
| BR (1) | BR112022025933A2 (https=) |
| CA (1) | CA3182325A1 (https=) |
| CL (1) | CL2022003719A1 (https=) |
| CO (1) | CO2022018653A2 (https=) |
| IL (1) | IL299256A (https=) |
| MX (1) | MX2022015757A (https=) |
| PE (1) | PE20231746A1 (https=) |
| SA (1) | SA522441857B1 (https=) |
| TW (1) | TW202216680A (https=) |
| WO (1) | WO2021262810A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| CN117561249A (zh) * | 2021-06-25 | 2024-02-13 | 细胞基因公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| CN110769822A (zh) * | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2020051260A1 (en) * | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 KR KR1020227044904A patent/KR20230027066A/ko active Pending
- 2021-06-23 PE PE2022003029A patent/PE20231746A1/es unknown
- 2021-06-23 CN CN202510574007.2A patent/CN120441548A/zh active Pending
- 2021-06-23 WO PCT/US2021/038618 patent/WO2021262810A1/en not_active Ceased
- 2021-06-23 CA CA3182325A patent/CA3182325A1/en active Pending
- 2021-06-23 TW TW110122923A patent/TW202216680A/zh unknown
- 2021-06-23 AU AU2021296833A patent/AU2021296833A1/en active Pending
- 2021-06-23 EP EP21827824.0A patent/EP4171566A4/en active Pending
- 2021-06-23 US US17/356,370 patent/US11634407B2/en active Active
- 2021-06-23 AR ARP210101735A patent/AR122723A1/es unknown
- 2021-06-23 JP JP2022580090A patent/JP7781792B2/ja active Active
- 2021-06-23 BR BR112022025933A patent/BR112022025933A2/pt unknown
- 2021-06-23 CN CN202180044295.0A patent/CN115835866B/zh active Active
- 2021-06-23 MX MX2022015757A patent/MX2022015757A/es unknown
- 2021-06-23 IL IL299256A patent/IL299256A/en unknown
-
2022
- 2022-12-22 CO CONC2022/0018653A patent/CO2022018653A2/es unknown
- 2022-12-22 CL CL2022003719A patent/CL2022003719A1/es unknown
- 2022-12-22 SA SA522441857A patent/SA522441857B1/ar unknown
-
2023
- 2023-03-16 US US18/122,496 patent/US12103920B2/en active Active
-
2024
- 2024-07-18 US US18/776,606 patent/US20250188056A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203650A patent/JP2026035702A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533203A5 (https=) | ||
| JP2023531709A5 (https=) | ||
| JP2023531495A5 (https=) | ||
| JP2024520481A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2022520448A5 (https=) | ||
| WO2021203768A1 (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2019094345A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2022510925A5 (https=) | ||
| JP7759877B2 (ja) | 治療用化合物 | |
| JP2021514001A5 (https=) | ||
| JP2025024130A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2015533782A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| RU2011125376A (ru) | Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы | |
| JP2015516420A5 (https=) | ||
| JP2024526191A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| JP2024516033A5 (https=) | ||
| JP2022514347A5 (https=) | ||
| JP2022534704A5 (https=) | ||
| JP2008513485A5 (https=) | ||
| JP2014514290A5 (https=) | ||
| JP2023553428A5 (https=) |